Newland Pharmaceutical's Levamlodipine Besylate API has been approved for marketing by China's National Medical Products Administration (NMPA), marking an important step in the company's expansion into cardiovascular APIs. The approval also offers formulation manufacturers a more reliable and cost-effective supply option.

List of Approved API Products

With continuous R&D investment and efficient registration & submission work, our company has established an API portfolio covering multiple therapeutic areas including anti-infectives, cardiovascular & cerebrovascular drugs, anesthetics & analgesics, gastrointestinal medicines, anti-allergy agents and iron supplements. The key products and their applications are listed below:

Pipeline Updates

Ruxolitinib Phosphate, Ilaprazole, and other products are progressing as planned. We will continue to expand our portfolio of specialty APIs and develop new products to create greater value for our customers.

Contact Us

For samples, quotations, or technical information, please contact us:

Tel: +86 138 1600 0664
Email: dma@newlandpharma.com

We look forward to exploring new opportunities with you.